Skip Navigation


Annals of Oncology Advance Access originally published online on February 21, 2008
Annals of Oncology 2008 19(4):821-822; doi:10.1093/annonc/mdn033
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/4/821    most recent
mdn033v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Blay, J.-Y.
Right arrow Articles by Ray-Coquard, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blay, J.-Y.
Right arrow Articles by Ray-Coquard, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)

The first 10% of the full text of this article appears below.

Pigmented villonodular synovitis (PVNS), also known as tenosynovial giant cell tumor (TGCT), is a rare pathological entity affecting the synovium in young adults [1, 2]. Initially considered as an inflammatory reactive process, recent observations have shown that this disease may actually be a benign neoplastic process with specific genetic alterations [3, 4]. . . . [Full Text of this Article]

funding

J.-Y. Blay1,2, H. El Sayadi2, P. Thiesse2, J. Garret3 and I. Ray-Coquard2

1 UJOMM Pavillon E, Hopital Edouard Herriot
2 INSERM U590, Department of Medicine, Department of Radiology Centre, Léon Bérard
3 Clinique du Parc, Lyon, France

Correspondence to: Prof. J.-Y. Blay, INSERM U590 Centre Léon Bérard, 28, rue Laennec, 69008 Lyon, France. E-mail: blay@lyon.fnclcc.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. G. Maki, D. R. D'Adamo, M. L. Keohan, M. Saulle, S. M. Schuetze, S. D. Undevia, M. B. Livingston, M. M. Cooney, M. L. Hensley, M. M. Mita, et al.
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
J. Clin. Oncol., July 1, 2009; 27(19): 3133 - 3140.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
V. O. Lewis
What's New in Musculoskeletal Oncology
J. Bone Joint Surg. Am., June 1, 2009; 91(6): 1546 - 1556.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Espinosa, A. H. Beck, C.-H. Lee, S. Zhu, K. D. Montgomery, R. J. Marinelli, K. N. Ganjoo, T. O. Nielsen, C. B. Gilks, R. B. West, et al.
Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma
Am. J. Pathol., June 1, 2009; 174(6): 2347 - 2356.
[Abstract] [Full Text] [PDF]